The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]
On September 10, 2014, The U.S. Food and Drug Administration (US FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) for anti-obesity treatments in combination with a reduced-calorie diet and exercise. Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California. The FDA approved the[…]
On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]
Topiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets[…]
The dramatic approval of Lorcaserin, now known by the trade name Belviq, was announced on June 27, 2012. Lorcaserin, CAS# 846589-98-8, is the first drug to be approved for weight loss in over twelve years. This announcement, made by representatives from both Easai and Arena Pharmaceuticals was a welcome one for researchers, patients and practitioners[…]
Intended for weight management, including weight loss and maintenance of weight loss, lorcaserin is poised to become the next weight loss drug. Lorcaserin is aimed at clinically obese patients, or patients with a Body Mass Index, or BMI, >30, or patients who are overweight (BMI >27) and have at least one weight related co-morbid condition.[…]
LGM Pharma supplies Topiramate, Bupropion, Naltrexone and Lorcaserin – Active Pharmaceutical Ingredients (APIs) used to treat obesity.